Ilva D. Rupenthal

Ilva D. Rupenthal

Buchanan Ocular Therapeutics Unit, University of Auckland

Affiliated withUniversity of Auckland

Research Area

Biography

Ilva is currently an Associate Professor and Deputy Head in the Department of Ophthalmology as well as the Director of the Buchanan Ocular Therapeutics Unit, which aims to develop and translate ocular therapeutic related scientific research into the clinical setting. She received a BPharm from the Philipps-University of Marburg, Germany, in 2003 and completed a PhD on ‘Ocular delivery of antisense oligonucleotides’ with the School of Pharmacy and the Department of Ophthalmology, University of Auckland, in 2008. In 2010, Ilva was awarded a prestigious three-year New Zealand Science and Technology Postdoctoral Fellowship to establish an ocular pharmaceutics group within the New Zealand National Eye Centre. In 2013, she then received a prestigious HRC Sir Charles Hercus Research Fellowship to continue her innovative research into stimuli-responsive ocular implants. Dr Rupenthal has received several awards including the 2016 HRC Emerging Researcher Excellence Award, a 2014 University of Auckland Early Career Research Excellence Award and most recently, a Humboldt Research Fellowship for Experienced Researchers.

JoVE Journal Publications

ArticleTotal : 1
Year
Characterization of a Novel Human Organotypic Retinal Culture Technique
Publication title

Cited by 2

2021

Other Publications

Article
Year
Comparison of ion-activated in situ gelling systems for ocular drug delivery. Part 1: physicochemical characterisation and in vitro release.

International journal of pharmaceutics| PubMed ID: 21453762

2011
2011
2011
2011
2012
2013
2013
2013
Dendrimers for gene delivery--a potential approach for ocular therapy?

The Journal of pharmacy and pharmacology| PubMed ID: 24635556

2014
Implants for drug delivery to the posterior segment of the eye: a focus on stimuli-responsive and tunable release systems.

Journal of controlled release : official journal of the Controlled Release Society| PubMed ID: 25307997

2014
Sustained intravitreal delivery of connexin43 mimetic peptide by poly(D,L-lactide-co-glycolide) acid micro- and nanoparticles--Closing the gap in retinal ischaemia.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V| PubMed ID: 25497487

2015
Neuroprotection in the treatment of glaucoma--A focus on connexin43 gap junction channel blockers.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V| PubMed ID: 25676338

2015
2015
Ocular delivery systems for topical application of anti-infective agents.

Drug development and industrial pharmacy| PubMed ID: 26325119

2016
Connexin43 in retinal injury and disease.

Progress in retinal and eye research| PubMed ID: 26432657

2016
2016
In vitro and ex vivo corneal penetration and absorption models.

Drug delivery and translational research| PubMed ID: 26762419

2016
2016
Modern approaches to the ocular delivery of cyclosporine A.

Drug discovery today| PubMed ID: 27080149

2016
2016
2018
Ocular drug delivery-eye on innovation.

Drug delivery and translational research| PubMed ID: 27766597

2016
2017
Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies.

Journal of controlled release : official journal of the Controlled Release Society| PubMed ID: 28087407

2017
Nanocarrier mediated retinal drug delivery: overcoming ocular barriers to treat posterior eye diseases.

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology| PubMed ID: 28425224

2018
Tonabersat Prevents Inflammatory Damage in the Central Nervous System by Blocking Connexin43 Hemichannels.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics| PubMed ID: 28560708

2017
2017
Ultrasound-mediated nanoparticle delivery across ex vivo bovine retina after intravitreal injection.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V| PubMed ID: 28602870

2017
2018
Drug-device combination approaches for delivery to the eye.

Current opinion in pharmacology| PubMed ID: 28843865

2017
2018
Overcoming ocular drug delivery barriers through the use of physical forces.

Advanced drug delivery reviews| PubMed ID: 28916492

2018
2018
2017
2017
Erratum to "Ultrasound-mediated nanoparticle delivery across ex vivo bovine retina after intravitreal injection" [Eur. J. Pharm. Biopharm. 119 (2017) 125-136].

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V| PubMed ID: 29222046

2018
2018
2017
Effects of enzymatic degradation on dynamic mechanical properties of the vitreous and intravitreal nanoparticle mobility.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences| PubMed ID: 29574081

2018
2018
2018
Drug delivery to the lens for the management of cataracts.

Advanced drug delivery reviews| PubMed ID: 29604375

2018
2018
2018
2018
2019
2019
Ultrasound-responsive nanobubbles for enhanced intravitreal drug migration: An ex vivo evaluation.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V| PubMed ID: 30660691

2019
2019
2019
2019
2019
2020
2019
Topical semifluorinated alkane-based azithromycin suspension for the management of ocular infections.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V| PubMed ID: 31195132

2019
2019
Connexin Hemichannel Block Using Orally Delivered Tonabersat Improves Outcomes in Animal Models of Retinal Disease.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics| PubMed ID: 31637594

2020
Validation of hyaluronic acid-agar-based hydrogels as vitreous humor mimetics for in vitro drug and particle migration evaluations.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V| PubMed ID: 31981693

2020
2020
Xentry-Gap19 inhibits Connexin43 hemichannel opening especially during hypoxic injury.

Drug delivery and translational research| PubMed ID: 32318976

2020
2020
2021
2021
2021
2020
2021
2020
2021
2021
2021
2021
2021